GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...

In other recent news, GSK plc has reported several significant developments. The company announced that the US FDA has accepted its Biologics License Application for depemokimab, targeting asthma ...

Big pharmaceutical companies have been making deals for technologies that could help them get their molecules through this protective membrane and now GSK is joining in, striking up an alliance ...

GSK) is steadily bolstering its pipeline. These include depemokimab for severe asthma and Blenrep for multiple myeloma. Overall, GSK ranks 1st on our list of most undervalued healthcare stocks to ...

(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent ...

In other recent news, GSK plc has reported several significant developments. The company announced that the US FDA has accepted its Biologics License Application for depemokimab, targeting asthma and ...